Dimensional Fund Advisors
MLYS icon

Dimensional Fund Advisors’s Mineralys Therapeutics MLYS Stock Holding History

Dimensional Fund Advisors’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.72M Sell
137,433
-203
-0.1% -$5.95K ﹤0.01% 2580
2025
Q4 		$4.99M Sell
137,636
-9,142
-6% -$367K ﹤0.01% 2527
2025
Q3 		$5.57M Sell
146,778
-40,606
-22% -$878K ﹤0.01% 2517
2025
Q2 		$2.54M Buy
187,384
+106,592
+132% +$1.54M ﹤0.01% 2704
2025
Q1 		$1.28M Buy
80,792
+64,380
+392% +$740K ﹤0.01% 2822
2024
Q4 		$202K Buy
+16,412
New +$215K ﹤0.01% 3166

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Dimensional Fund Advisors's MLYS Position: Q1 2026 in Review

Dimensional Fund Advisors reduced its Mineralys Therapeutics (MLYS) stake by 0.15% in Q1 2026, selling an estimated $5.95K and leaving 137,433 shares worth $3.72M. The position accounts for ﹤0.01% of the portfolio, ranked #2580.

Dimensional Fund Advisors first reported a position in MLYS in Q4 2024 and has held it in 6 quarters since. The position peaked at $5.57M in Q3 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Dimensional Fund Advisors held 137,433 shares of Mineralys Therapeutics worth $3.72M as of Q1 2026.
  • Dimensional Fund Advisors sold 203 Mineralys Therapeutics shares in Q1 2026, an estimated $5.95K.
  • Mineralys Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q1 2026, its #2580 holding.
  • Dimensional Fund Advisors first reported a position in Mineralys Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Dimensional Fund Advisors's Mineralys Therapeutics position peaked at $5.57M in Q3 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.